Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 169
- 主要终点
- Recurrent thrombosis
研究概览
简要总结
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:
• Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.
详细描述
Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion.
Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Here's a polished version of your Inclusion and
排除标准
- •section with grammar, spelling, and phrasing corrected for clarity and formal research style:
- •Inclusion Criteria
- •Adult patients aged ≥18 years
- •Histopathologically confirmed cancer
- •Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)
- •Received anticoagulation therapy for at least six months Exclusion Criteria
- •Patients who do not meet the inclusion criteria
研究组 & 干预措施
Therapeutic dose anticoagulant group
including patients with the standard therapeutic dose-administered after the initial six-month treatment period.
干预措施: Anticoagulant (Drug)
Prophylactic dose anticoagulant group
including patients with the doses lower than therapeutic dose-administered at any point after the initial six-month treatment period.
干预措施: Anticoagulant (Drug)
结局指标
主要结局
Recurrent thrombosis
时间窗: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.
cumulative incidence of recurrent thrombosis
次要结局
- Anticoagulant related bleeding(After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.)
- Overall survival(The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.)
研究者
Lantarima Bhoopat
Hematology, Internal medicine, Faculty of medicine
Thammasat University